ContraFect Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CFRX Nasdaq 2834 https://www.contrafect.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ContraFect Corp

CFRX: New Data on Exebacase Shows Rapid Resolution of Symptoms in Phase 2 Trial… - Oct 12th, 2021 10:26 am
ContraFect’s New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia - Oct 4th, 2021 1:00 pm
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021 - Sep 29th, 2021 11:30 am
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference - Sep 22nd, 2021 11:30 am
CFRX: Awaiting Interim Futility Analysis for Phase 3 DISRUPT Trial… - Aug 30th, 2021 11:18 am
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update - Aug 13th, 2021 11:30 am
Were Hedge Funds Right About ContraFect Corp (CFRX)? - Jul 28th, 2021 2:27 am
CFRX: Presentations at ECCMID Highlight Advances in Lysin Platform… - Jul 26th, 2021 9:53 am
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID - Jul 19th, 2021 11:31 am
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity - Jul 19th, 2021 11:30 am
What You Need To Know About ContraFect Corporation's (NASDAQ:CFRX) Investor Composition - Jun 28th, 2021 6:54 am
2 “Strong Buy” Penny Stocks With Massive Upside Potential - Jun 24th, 2021 2:42 pm
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development - Jun 17th, 2021 11:31 am
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum - Jun 17th, 2021 11:30 am
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections - May 26th, 2021 11:30 am
CFRX: Interim Futility Analysis for Phase 3 DISRUPT Trial in 2H21… - May 24th, 2021 12:19 pm
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update - May 14th, 2021 11:30 am
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office - May 3rd, 2021 11:30 am
ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium - Apr 26th, 2021 11:30 am
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit - Apr 15th, 2021 10:30 pm